On Mar. 2, 2021, the NIH announced it had launched the next version of the Accelerating Medicines Partnership (AMP) Alzheimer’s disease program to expand the open science, big data approach for identifying biological targets for therapeutic intervention.

AMP AD 2.0 supported new technologies, including cutting-edge, single-cell profiling and computational modeling, to enable a precision medicine approach to therapy development.